Aspire BioPharma is trading 5% up at $8.95, with no fresh company-specific catalyst identified.
- Shares rose from the August 28 close of $8.51.
- No fresh August 31, 2026 company-specific announcement, filing, or stated catalyst was identified; available coverage is older acquisition and buyback news, with no reported connection to the current move.
- The broader market is declining, so the gain does not clearly track overall index sentiment.